Rohit Loomba Selected Research

firsocostat

1/2022	Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
1/2022	Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
7/2021	Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
1/2021	Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH.
12/2018	Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
11/2018	GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rohit Loomba Research Topics

Disease

132	Non-alcoholic Fatty Liver Disease 10/2022 - 08/2007
104	Fibrosis (Cirrhosis) 11/2022 - 04/2009
35	Liver Cirrhosis (Hepatic Cirrhosis) 10/2022 - 05/2013
32	Liver Diseases (Liver Disease) 11/2022 - 10/2009
18	Alcoholic Fatty Liver 01/2022 - 03/2015
17	Inflammation (Inflammations) 01/2022 - 02/2014
15	Hepatocellular Carcinoma (Hepatoma) 02/2022 - 01/2014
14	Fatty Liver 01/2022 - 10/2009
13	Insulin Resistance 01/2021 - 08/2007
10	Obesity 12/2021 - 04/2008
9	Infections 01/2021 - 04/2009
8	Hypertension (High Blood Pressure) 07/2022 - 09/2010
8	Chronic Hepatitis B 01/2022 - 01/2006
7	Weight Loss (Weight Reduction) 01/2022 - 10/2009
7	Neoplasms (Cancer) 01/2022 - 04/2008
7	Type 2 Diabetes Mellitus (MODY) 01/2021 - 09/2014
7	Hepatitis B 01/2020 - 01/2006
6	Pruritus (Itching) 01/2022 - 03/2015
5	COVID-19 01/2021 - 01/2020
5	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 09/2010
4	Diabetes Mellitus 01/2022 - 01/2013
4	Body Weight (Weight, Body) 11/2021 - 08/2007
4	Alcoholic Liver Diseases (Alcoholic Liver Disease) 12/2018 - 01/2015
3	Liver Neoplasms (Liver Cancer) 01/2022 - 10/2020
3	Weight Gain 10/2021 - 08/2007
3	Liver Failure 01/2018 - 04/2008
3	Hemorrhage 10/2017 - 01/2013
3	Carcinogenesis 12/2016 - 05/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2012
2	Fatigue 01/2022 - 07/2021
2	Dyslipidemias (Dyslipidemia) 01/2022 - 09/2010
2	Portal Hypertension 01/2022 - 10/2017
2	Alcoholism (Alcohol Abuse) 01/2022 - 01/2015
2	Edema (Dropsy) 10/2021 - 01/2020
2	Nausea 10/2021 - 12/2019
2	Disease Progression 01/2021 - 01/2017

Drug/Important Bio-Agent (IBA)

51	Biomarkers (Surrogate Marker)IBA 10/2022 - 12/2010
41	Protons (Proton)IBA 01/2022 - 01/2013
19	Alanine Transaminase (SGPT)IBA 01/2021 - 08/2007
17	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2022 - 04/2008
13	nasIBA 10/2022 - 09/2016
12	obeticholic acidIBA 01/2022 - 03/2015
11	Triglycerides (Triacylglycerol)IBA 07/2022 - 09/2010
10	CollagenIBA 06/2022 - 01/2017
9	Pharmaceutical PreparationsIBA 01/2022 - 04/2009
9	Insulin (Novolin)FDA Link 01/2021 - 10/2009
9	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 08/2015
8	Bile Acids and Salts (Bile Acids)IBA 01/2022 - 03/2015
6	Proteins (Proteins, Gene)FDA Link 11/2022 - 04/2009
6	firsocostatIBA 01/2022 - 11/2018
6	Antiviral Agents (Antivirals)IBA 01/2022 - 10/2009
6	selonsertibIBA 01/2022 - 01/2018
6	LipidsIBA 11/2021 - 02/2014
6	EnzymesIBA 11/2021 - 10/2009
6	BilirubinIBA 01/2021 - 12/2010
6	Ethanol (Ethyl Alcohol)IBA 01/2021 - 01/2015
5	Pioglitazone (Actos)FDA Link 10/2021 - 08/2007
5	CholesterolIBA 01/2021 - 03/2013
5	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2019 - 04/2008
4	HDL CholesterolIBA 07/2022 - 01/2012
4	cilofexorIBA 01/2022 - 01/2021
4	Vitamin E FDA LinkGeneric 10/2021 - 05/2014
3	clonidine-displacing substance (ClDS)IBA 01/2022 - 10/2017
3	Tenofovir (Viread)FDA Link 01/2022 - 10/2015
3	TransferasesIBA 01/2022 - 11/2010
3	simtuzumabIBA 01/2022 - 01/2018
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2017
3	Glucagon-Like Peptide-1 Receptor AgonistsIBA 12/2021 - 01/2021
3	Keratin-18 (Keratin 18)IBA 01/2021 - 12/2014
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 01/2020
3	Transaminases (Aminotransferases)IBA 01/2021 - 09/2016
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 12/2020 - 11/2010
3	cenicrivirocIBA 01/2020 - 01/2018
3	LigandsIBA 12/2019 - 03/2015
3	LDL Lipoproteins (beta Lipoproteins)IBA 10/2019 - 09/2010
3	Hemoglobins (Hemoglobin)IBA 10/2019 - 11/2016
3	AlbuminsIBA 07/2015 - 12/2010
3	Metformin (Glucophage)FDA LinkGeneric 12/2014 - 10/2009
3	Interleukin-6 (Interleukin 6)IBA 10/2013 - 01/2012
2	LDL CholesterolIBA 07/2022 - 01/2020
2	Acetyl-CoA CarboxylaseIBA 01/2022 - 12/2018
2	entecavir FDA Link 01/2022 - 01/2021
2	Complement System Proteins (Complement)IBA 01/2022 - 01/2018
2	gadolinium ethoxybenzyl DTPA FDA Link 01/2022 - 11/2019
2	semaglutideIBA 01/2022 - 11/2021
2	Biological ProductsIBA 01/2022 - 01/2017
2	Oxidoreductases (Dehydrogenase)IBA 01/2022 - 01/2021
2	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 10/2015
2	lanifibranorIBA 10/2021 - 10/2021
2	Drug CombinationsIBA 07/2021 - 01/2021
2	PegbelferminIBA 01/2021 - 12/2019
2	Carrier Proteins (Binding Protein)IBA 01/2021 - 12/2020
2	aldaferminIBA 01/2021 - 01/2018
2	Proton Pump InhibitorsIBA 01/2021 - 10/2017

Therapy/Procedure

46	Therapeutics 01/2022 - 01/2006
11	Liver Transplantation 05/2022 - 06/2008
7	Drug Therapy (Chemotherapy) 12/2021 - 04/2008
4	Aftercare (After-Treatment) 01/2022 - 06/2015
2	Precision Medicine 01/2021 - 01/2020
2	Bariatric Surgery 01/2021 - 01/2018